I believe $RNXT has great potential given its recent Q3 results, especially with the progress in their Phase III clinical trial and a promising low float. I'm confident that as trial catalysts and good news roll in, the stock will see a nice upward movement.

I just bought some RNXT shares after seeing its strong recovery and positive technical indicators. The breakout above key resistance levels and increased trading volume suggest that this uptrend could continue, especially with growing demand for their RenovoCath system paving the way for future revenue growth.

I believe $RNXT is poised for a bounce off the $1 support after its recent 24% surge. The strong volume on Friday and positive news about ongoing clinical trials indicate that this could be a great swing trade opportunity for recovery.

With the positive early-stage clinical data showing significant improvement in overall survival for LAPC patients using the TAMP platform, RNXT is set to benefit as its Phase III trial progresses, making it a good swing trade opportunity.